Antiviral resistance and hepatitis B therapy. - Wikidata - wikimedia - TriplyDB

Antiviral resistance and hepatitis B therapy.

Antiviral resistance and hepatitis B therapy.

http://www.wikidata.org/entity/Q37255008

about

Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing rtM204Q may serve as a novel lamivudine-resistance-associated mutation of hepatitis B virus Hepatitis B virus molecular biology and pathogenesis Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis.Lamivudine plus adefovir combination therapy versus entecavir monotherapy for lamivudine-resistant chronic hepatitis B: a systematic review and meta-analysis.Detection of hepatitis B virus genotypic resistance mutations by coamplification at lower denaturation temperature-PCR coupled with sanger sequencing.Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.Systematic review of the literature on comparative effectiveness of antiviral treatments for chronic hepatitis B infection.Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis.Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.An autophagosome-based therapeutic vaccine for HBV infection: a preclinical evaluation.2-amino-N-(2,6-dichloropyridin-3-yl)acetamide derivatives as a novel class of HBV capsid assembly inhibitor.Subversion of cellular autophagy machinery by hepatitis B virus for viral envelopment Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis Genotypic resistance profiles in Chinese patients with chronic hepatitis B virus infection and the efficacy of nucleoside analog rescue therapy.Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients.The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine.Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis.Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B On-treatment HBV DNA dynamics predict virological breakthrough in entecavir-treated HBeAg-positive chronic hepatitis B Comparison of the efficacy of tenofovir monotherapy versus tenofovir-based combination therapy in adefovir-experienced chronic hepatitis B patients: a systematic review and meta-analysis Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures Mutation Changes in the preC/Core Promoter in HBeAg-Positive Patients With Chronic Hepatitis B During Interferon Therapy.Hepatoprotective effect of commercial herbal extracts on carbon tetrachloride-induced liver damage in Wistar rats.Tenofovir in treatment of Iranian patients with chronic hepatitis B virus infection: An open-label case series.The anti-HBV effect mediated by a novel recombinant eukaryotic expression vector for IFN-α Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients Rapid detection of hepatitis B virus variants associated with lamivudine and adefovir resistance by multiplex ligation-dependent probe amplification combined with real-time PCR.Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).Entecavir for the long-term treatment of chronic hepatitis B.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?Chronic viral hepatitis in kidney transplantation.Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.Recent advances in the treatment of chronic hepatitis B.

P2860

Q26765932-572B16DA-7313-40F4-9411-154124A71105 Q28482355-90B05AE5-91B7-4C5C-AAFE-7632077FAF05 Q28540082-CADAF9EB-AE3C-4B8C-99BF-0142C7C2EA1F Q28818406-524046B4-7BC7-43EC-B1C5-F037D507FC95 Q30234870-2C31CE57-0005-410F-ABBD-2FE40F95FF9F Q33920626-A674B5E5-152E-497A-84D2-994A61AB2414 Q33985364-9FEC8A1D-693D-4DB7-BC48-67EE4C6764B2 Q34058707-A87A95E3-C115-403F-9F75-DE84A641A359 Q34471072-DE3C9400-9E28-4B0C-AE74-30663CF2AB4B Q34594403-9772B7C1-47D3-4C67-9DD0-8A0EE7F53D5B Q34623662-6641BE18-9F2D-4D40-A7E1-F3A99AE9670A Q34948124-043C80E8-61F2-41A8-A0E3-62DFE311835F Q34995374-816E1315-5832-45DB-B9EF-BCCEA480CF86 Q35076698-C7AE732C-8367-45F4-BEA9-8225B3E03CE2 Q35077605-44F52DB8-1353-444D-99EF-3BFD3B650FDA Q35132805-40225798-EEBD-4342-9E0F-9132C5FAF451 Q35186029-2DEC9A72-9E65-4164-AFF5-30F2F12DE799 Q35375654-95E0B53A-8500-4593-81CD-7AAFEADC2E4A Q35540256-36473F96-90AA-413D-B3CE-100E4C307A41 Q35694422-C5720B34-31DD-4662-AAC6-B620B173FE10 Q35755608-A7745949-C15E-4F49-82C4-88DE2566D145 Q35833216-22F0D71D-0585-45BB-9819-75E9ABA3DAAA Q36154994-6E424FCA-F594-4948-B2EA-EFF36396996A Q36238754-CDF2B5BA-2AAC-4C9E-9180-57E92A9F4191 Q36325645-11C30641-C77D-4846-9422-F37F2D96BDDE Q36492635-B1D4928D-2054-4A7B-A9CA-1A4C7D44A5A6 Q36492640-69EFFF53-6575-4F7E-B6B9-3F455ED15B48 Q36566914-867249B8-CE9C-4D69-A728-C0DC47A012DD Q37034996-EC74FDA3-392C-499D-9CAD-4850FBCA8CB8 Q37137734-BF076A3A-6F40-47B9-AAF3-960274A54D49 Q37153828-75128DB6-C809-4B90-9DA6-C43B56A9535F Q37334120-7021393C-B636-4458-9120-F215B92EB622 Q37409858-704F8BCB-61CB-438B-AFCF-BF37C1E08950 Q37546232-7F25358E-02CE-44C8-8CBF-C9F48B62B3F3 Q37606534-A90D4A65-E02A-42D5-B13D-9CC78CD1DC6E Q37626058-8356478F-6B93-44F8-B755-9ECDFE40EED3 Q37825532-C2C6652D-A66A-4D77-98F5-2A46D059EFA4 Q37833898-7641125B-6FEA-4540-95C3-20ACD1DFAFE4 Q37886893-032ED9D7-61E0-4631-84E6-1E332EC39BEC Q37891094-3CCAC28C-5C24-4E07-B065-D6F9218A8E70

P2860

Antiviral resistance and hepatitis B therapy.

http://www.wikidata.org/entity/Q37255008

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiviral resistance and hepatitis B therapy.

@en

Antiviral resistance and hepatitis B therapy.

@nl

type

label

Antiviral resistance and hepatitis B therapy.

@en

Antiviral resistance and hepatitis B therapy.

@nl

prefLabel

Antiviral resistance and hepatitis B therapy.

@en

Antiviral resistance and hepatitis B therapy.

@nl

P1433

Q37255008-5E3BCC52-AFD7-41B3-B71F-B32F2FFAE016

P1476

Q37255008-7B7878EF-FA73-48B7-90F7-2696FBECF8E9

P2093

Q37255008-1A7CE158-FE7E-496C-BF8A-605D98AF43E9

Q37255008-95EE6DE4-5199-45F5-8ABF-B2A99838A099

P2860

Q37255008-03DCA00F-92B5-4C82-BEAF-F06F9CBE5645

Q37255008-0A8B0306-2D10-40B8-BAA3-F0573FC50609

Q37255008-14297DDF-CE66-4C26-AB4D-00A384AD9431

Q37255008-1BAC8DCF-C844-4110-80ED-D3E5836FC659

Q37255008-1BB721F7-FF67-4761-952C-E5522E759EB0

Q37255008-1C477A67-5E19-4448-9121-271F703252D3

Q37255008-1E2B7D2B-19EE-4CF2-A0D5-F9E6E5DC4D59

Q37255008-2238B0BA-FBBC-4BA7-B086-C95EC6C3EB9E

Q37255008-255E3AC9-3559-4C11-93D3-58B338A9FF43

Q37255008-285FF2F7-C983-44E9-8548-4E463C075474

P304

Q37255008-B31C9509-93D8-412F-892F-0173311A8EDF

P31

Q37255008-37F18D9F-A476-49D6-9CF3-005CB3A63635

P356

Q37255008-CC3EB852-B886-4F7A-9470-B9F9C926DBBC

P407

Q37255008-C7B143AB-8F4B-4E8D-B10A-CF8022065431

P433

Q37255008-BB8E92BE-309D-4474-8017-8BA09E7F1C9B

P478

Q37255008-0CB18829-1604-4E6E-8B21-EC07B1048A52

P577

Q37255008-F94A1E45-1FCA-4ECE-8E8D-AB96560500EA

P5875

Q37255008-ABFD0899-6A6A-4AAF-A72E-5D3B5B60F756

P698

Q37255008-00AF491A-60AA-4B29-A246-92B204990050

P932

Q37255008-22124CBE-0CD6-4750-93DC-EC98B77BFCDF

P356

P1433

P1476

Antiviral resistance and hepatitis B therapy.

@en

P2093

Edward C Doo

http://www.w3.org/2001/XMLSchema#string

Marc G Ghany

http://www.w3.org/2001/XMLSchema#string

P2860

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

Telbivudine versus lamivudine in patients with chronic hepatitis B

The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments.

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.

Low dynamic state of viral competition in a chronic avian hepadnavirus infection.

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine

P304

S174-84

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22900

http://www.w3.org/2001/XMLSchema#string

P407

P433

5 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24366790

http://www.w3.org/2001/XMLSchema#string

P698

19399794

http://www.w3.org/2001/XMLSchema#string

P932

2707848

http://www.w3.org/2001/XMLSchema#string